Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapanisertib QTc study in advanced solid tumors
NCT02197572Phase 1Completed
- Sponsor
- Calithera Biosciences
- Start
- Sep 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sapanisertib in solid tumor (advanced stage), sponsored by Calithera Biosciences. Primary endpoint: Individual Baseline Corrected Rate-Corrected QT Interval. Started Sep 2014; status: completed.
02
Drugs
sapanisertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02197572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02197572.